



FOR IMMEDIATE RELEASE

ENDOSENSE UNVEILS FIVE GROUNDBREAKING ABSTRACTS
ON CONTACT FORCE MEASUREMENT FOR CATHETER ABLATION

SAN FRANCISCO – May 13, 2008 – Endosense, a medical technology company focused on enabling the broad adoption of catheter ablation for the treatment of cardiac arrhythmias, has announced that it will debut five groundbreaking abstracts in support of its TactiCath™ force-sensing ablation catheter at Heart Rhythm 2008, the Heart Rhythm Society’s 29th Annual Scientific Sessions, in San Francisco, May 14 - 17.

The abstracts report data from three U.S. and two European studies, which were conducted by Dipen Shah, M.D., University Hospital of Geneva; and Hiroshi Nakagawa, M.D., Ph.D., and Warren Jackman, M.D, University of Oklahoma. The results of the studies indicate that accurate, real-time measurement of the contact force at the catheter tip can have a major positive impact on the safety and efficacy of radiofrequency catheter ablation procedures. In particular, the results suggest that:

- Accurate measurement of contact force has the potential to prevent complications, such as esophageal lesions, perforations and pops
- The force required to perforate through an ablation lesion is significantly lower than that required to perforate through healthy tissue, and
- Alternate measurement techniques, including electrogram parameters and impedance, are poor predictors of electrode-tissue contact force in radiofrequency catheter ablation.

“Our preclinical studies clearly show that accurate, reliable force control will be critical for increasing the safety and effectiveness of the catheter ablation procedure. I expect this new force-sensing technology to provide an important new alternative to current manual catheters, while also decreasing the steep learning curve and facilitating the development of remote navigation,” said Dr. Nakagawa.

- more -

Endosense's TactiCath is the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Without this measure, electro-physiologists have had to estimate – and frequently guess – the level of contact force required, as too little force may render the procedure ineffective and too great a force may perforate the heart wall.

“The TactiCath technology will alter the way electro-physiologists control ablation lesion formation,” added Dr. Shah. “This will have a major positive impact on acute ablation efficacy as well as the prevention of recurrences and complications related to mechanical force and collateral damage.”

TactiCath is a high-end, 8.5F sheath compatible, open irrigated, steerable catheter that seamlessly integrates Endosense's proprietary Touch+™ fiber optic sensor technology at the catheter tip. It has undergone extensive preclinical testing in the United States and Europe. Endosense's growing body of study data on TactiCath has been the subject of nine abstracts presented at annual meetings of the Heart Rhythm Society, American College of Cardiology and American Heart Association.

The first human trial of TactiCath is slated to occur in Europe in mid-2008, with CE Mark expected in 2009. TactiCath is currently limited to investigational use only by the U.S. Food and Drug Administration.

About Heart Rhythm 2008

Heart Rhythm 2008 takes place May 14-17 at the Moscone Convention Center in San Francisco. The meeting is the most comprehensive educational event on heart rhythm disorders, offering 250 educational opportunities in multiple formats. The world's most renowned scientists and physicians will present a wide range of heart rhythm topics including advances in statins, cardiac resynchronization therapy, catheter ablation, cardiac pacing and heart failure and the latest technology, including state-of-the-art pacemakers and defibrillators. www.HRSonline.org

About Endosense

Founded in Geneva in 2003, Endosense is a medical technology company focused on enabling the broad adoption of catheter ablation for the treatment of cardiac arrhythmias. The company has pioneered the use of contact force measurement in catheter ablation, with the development of its proprietary Touch+™ sensor technology. Endosense's flagship product is the TactiCath™, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. For more information, visit www.endosense.com.

MEDIA CONTACT/U.S.:

Laura Nobles
Nobles Communications
310-795-0497
laura@noblescommunications.com

MEDIA CONTACT/EUROPE:

Danièle Letore
Genevensis
+41 22 779 06 20
info@genevensis.com

###